Abstract
Estimates suggest that approximately 30% of patients with chronic urticaria (CU) are refractory to antihistamines, [1] Najib U. Bajwa Z. Ostro M. Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2009; 103: 496-501 Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar a disease characteristic that, in our experience, frequently results in the use of corticosteroids to control acute flares and maintain remission. Reluctance may exist on the part of the patient or physician to use immunomodulatory medications as steroid-sparing agents in the treatment of this frustrating condition because of adverse side effects, need for laboratory monitoring, and uncertainty of outcome. We recently conducted a retrospective chart review to determine the relative effectiveness and safety of immunomodulatory therapies used in our tertiary clinic practice to treat antihistamine-refractory CU.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
